The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRI-cetuximab: A multicenter phase II proof-of-concept study of a tailored triple combination therapy for safe dose intensification.
Michele Boisdron-Celle
No relevant relationships to disclose
Olivier Capitain
No relevant relationships to disclose
Jean-Philippe Metges
No relevant relationships to disclose
Antoine Adenis
No relevant relationships to disclose
Jean-Luc Raoul
No relevant relationships to disclose
Thierry Lecomte
No relevant relationships to disclose
You Heng Lam
No relevant relationships to disclose
Roger Faroux
No relevant relationships to disclose
Claude Masliah
No relevant relationships to disclose
Anne-Lise Septans
No relevant relationships to disclose
Virginie Berger
No relevant relationships to disclose
Alain Morel
No relevant relationships to disclose
Erick Gamelin
No relevant relationships to disclose